Idiopathic Normal Pressure Hydrocephalus (INPH) Clinical Trial
— NPH wearablesOfficial title:
Walking Pattern Characteristics in Normal Pressure Hydrocephalus. A Phase I/II Open-label Single Center Trial to Characterize Disease-specific Walking Patterns Using Wearable Gyroscopes
Verified date | April 2024 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
20 patients who are diagnosed with NPH receive a set of 5 wearable gyroscopes (IMUs, ZurichMove sensors) for a period of 3 days for measurement and characterization of their walking in an ambulatory setting. At a follow-up 2 weeks to 6 months after CSF diversion surgery, the examination is repeated and improvement is measured. The data will be compared with a healthy group of 20 age- and gender-matched individuals as well a a group of 20 young individuals.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 25, 2024 |
Est. primary completion date | April 25, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Age limits for the NPH patient group and the matched healthy vonunteers group are 60-100 years. Age limits for the young healthy volunteers group are 18-40 years. Inclusion Criteria: NPH patient group: 1. Informed Consent as documented by signature prior to any study related procedures or informed consent by a legal representative in case of cognitive deficits. 2. Male and female patients alike 3. Age between 60 and 100 years 4. Clinical suspect for NPH 5. Significant improvement (by more than 10%) in walking speed or endurance in a standardized CSF-TAP test (of at least 35 ml CSF). 6. Planned implantation of a VP shunt for NPH treatment (independently from the study). Matched controls group: 1. Informed Consent as documented by signature prior to any study related procedures 2. Male and female patients alike (matched to group 1) 3. Age between 60 and 100 years (matched to group 1) 4. No clinical suspect for NPH or any other movement disorder Young controls group: 1. Informed Consent as documented by signature prior to any study related procedures 2. Male and female patients alike (matched to group 1) 3. Age between 18 and 40 years 4. No clinical suspect for NPH or any other movement disorder Exclusion Criteria: 1. Enrolment of the investigator, his/her family members, employees and other dependent persons (only for patients; no exclusion criteria for controls), 2. Apparent or suspected movement disorder or other known disorder, which might affect normal standing or walking 3. Cardiovascular disorders, which might affect physical resilience 4. Pregnant women 5. Pre-menopausal state of female patients and probands in groups 1 and 2. 6. Children and adolescents |
Country | Name | City | State |
---|---|---|---|
Switzerland | Dept. of Neurosurgery, Zurich University Hospital | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich | ETH Zurich |
Switzerland,
Renggli D, Graf C, Tachatos N, Singh N, Meboldt M, Taylor WR, Stieglitz L, Schmid Daners M. Wearable Inertial Measurement Units for Assessing Gait in Real-World Environments. Front Physiol. 2020 Feb 20;11:90. doi: 10.3389/fphys.2020.00090. eCollection 2020. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Walking characteristics | Complex walking pattern comprising of stride length, width, frequency (altogether one parameter) | Between 2 weeks to 6 months after CSF diversion surgery | |
Secondary | 4 minutes timed Walk test | Standard test (seconds) | immediately after fixation of IMUs | |
Secondary | 180 degree turnaround test | Participants are asked to turn by 180 degrees. Steps needed are counted. | immediately after fixation of IMUs | |
Secondary | Kiefer score | Standard score for iNPH severity, only patient group; range 0-26; higher indicates higher severity | before surgery | |
Secondary | Kiefer score | Standard score for iNPH severity, only patient group; range 0-26; higher indicates higher severity | after surgery (range 2 weeks to 6 months) | |
Secondary | Stein and Langfitt score | Standard score for patient independence, only patient group; range 0-IV; higher indicates higher dependency | before surgery | |
Secondary | Stein and Langfitt score | Standard score for patient independence, only patient group; range 0-IV; higher indicates higher dependency | after surgery (range 2 weeks to 6 months) | |
Secondary | NPH recovery rate | Standard rate for success of CSF diversion treatment in NPH. Calculated as follows: (Kiefer score preoperatively - Kiefer score postoperatively) / Kiefer score preoperatively x 10; range 0-10; Higher indicates better response to surgery | after surgery (range 2 weeks to 6 months) | |
Secondary | Evan´s Index | Standard descriptor for width of lateral ventricles in iNPH. Calculated as maximum with of frontal horns / maximal diameter of brain in axial CT or MRI at the level of cella media; range: 0-1; higher indicates larger ventricles and more severe hydrocephlaus | before surgery | |
Secondary | Disproportionally Enlarged Subarachnoidal space Hydrocephalus (DESH) sign | Positivity of standard sign in preoperative CT or MRI imaging, hinting at presence of iNPH. Values: Positive/Negative | before surgery | |
Secondary | Time from appearance of first symptoms to surgery | From first appearance of symptoms to surgery in years | before surgery | |
Secondary | 3-dimensional characterization of walking patterns | Detailed analysis of walking patterns recorded during the measurement phases by the wearable IMUs. | before surgery | |
Secondary | 3-dimensional characterization of walking patterns | Detailed analysis of walking patterns recorded during the measurement phases by the wearable IMUs. | after surgery (range 2 weeks to 6 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03350750 -
A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
|
N/A | |
Recruiting |
NCT05081128 -
Efficacy in iNPH Shunting (PENS) Trial
|
N/A | |
Recruiting |
NCT04975269 -
Acetazolamide Trial in Normal Pressure Hydrocephalus
|
Phase 2 | |
Completed |
NCT05204745 -
Ventriculomegaly and Gait Disturbance in the Senior Population in the Region of Västerbotten
|